Modified/Targeted EGFR Inhibitor
Chronic Neuropathic Pain
DiscoveryActive
Key Facts
About AKIGAI
AKIGAI is a private, preclinical-stage biotech company founded in 2020 in Oslo, Norway, focused on developing disruptive drugs for neuropathic pain. The company's foundation is the serendipitous discovery and subsequent patenting of the use of EGFR inhibitors for neuropathic pain relief, supported by preclinical research and clinical observations in over 100 patients across 10 clinics. AKIGAI is pursuing a dual-path development strategy involving both tyrosine kinase inhibitors and monoclonal antibodies, and is actively seeking partners to advance its programs toward clinical validation and commercialization.
View full company profileTherapeutic Areas
Other Chronic Neuropathic Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| Amitriptyline/Gabapentin/Ketoprofen in Pentravan® | Fagron | Approved/Commercial |
| EGFR Inhibitor (Tyrosine Kinase Inhibitor - oral) | AKIGAI | Preclinical |
| EGFR Inhibitor (Monoclonal Antibody - parenteral) | AKIGAI | Preclinical |